Harmony Biosciences Holdings (HRMY) Income Statement
An income statement shows a company's revenue, expenses, and profit over a reporting period.
Harmony Biosciences Holdings, Inc., a commercial-stage pharmaceutical company, focuses on developing and commercializing therapies for patients with rare neurological diseases in the United States.
Total Revenue Chart for Harmony Biosciences Holdings
Harmony Biosciences Holdings (HRMY) revenue for FY2025 was USD 868.5M, a 21.5% change from FY2024. Harmony Biosciences Holdings's revenue moved from USD 0.00 in 2018 to USD 868.5M in 2025 over 7 years. Earnings per share moved from USD -1.42 in 2018 to USD 2.97 in 2022. Revenue compound annual growth rate: 5-year CAGR of 40.3%.
Total Revenue (US Dollars)
R&D as % of Revenue
Compare with
Key Stats
- Market Cap
- $2.10B
- Implied Share Price
- $36.13
- Enterprise Value
- $1.91B
- Revenue (TTM)
- $959.90M
- EBITDA
- $255.99M
- Profit Margin
- 18.88%
- Trailing P/E
- 11.65
- Forward P/E
- 10.32
- Price/Book (MRQ)
- 2.42
- Price/Sales (TTM)
- 2.19
- EV/EBITDA
- 6.80
- EV/Revenue
- 1.98
- Dividend Yield
- —
- Book Value
- $17.19
- Free Cash Flow (FY2025)
- $347.89M
- Free Cash Flow Yield
- 16.53%
Snapshot as of 24th October 2026 — not point-in-time controlled, may lag the live market by a few days.